Research programme: complement system inhibitors- True North TherapeuticsAlternative Names: TNT 010
Latest Information Update: 15 Dec 2015
At a glance
- Originator True North Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Complement system protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 15 Dec 2015 Preclinical trials in Undefined indication in USA (Parenteral) (True North Therapeutics pipeline; December 2015)